In the healthcare industry, drug pricing discussions often start and end with list price. Public debate usually revolves around annual list price increases, policymakers argue for transparency, and headlines emphasize wholesale acquisition cost (WAC). However, list price is just the beginning for payers, providers, and health systems responsible for overseeing actual budgets. The true financial impact is found in the net price, influenced by rebates, discounts, fees, and contractual…
